Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer
NCT02022852Phase 2Unknown
- Sponsor
- Harbin Medical University
- Start
- Jul 2013
- Primary completion
- Jul 2015
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in rectal cancer, sponsored by Harbin Medical University. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02022852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022852.